- Home
- XBIO vs EDSA Comparison
XBIO vs EDSA Comparison
Compare XBIO & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- EDSA
- Stock Information
- Founded
- XBIO N/A
- EDSA 2015
- Country
- XBIO United States
- EDSA Canada
- Employees
- XBIO N/A
- EDSA N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- EDSA Health Care
- Exchange
- XBIO Nasdaq
- EDSA Nasdaq
- Market Cap
- XBIO 5.8M
- EDSA 6.2M
- IPO Year
- XBIO N/A
- EDSA N/A
- Fundamental
- Price
- XBIO $2.67
- EDSA $2.45
- Analyst Decision
- XBIO Hold
- EDSA Strong Buy
- Analyst Count
- XBIO 1
- EDSA 1
- Target Price
- XBIO N/A
- EDSA $21.00
- AVG Volume (30 Days)
- XBIO 6.9K
- EDSA 32.2K
- Earning Date
- XBIO 03-18-2025
- EDSA 05-09-2025
- Dividend Yield
- XBIO N/A
- EDSA N/A
- EPS Growth
- XBIO N/A
- EDSA N/A
- EPS
- XBIO N/A
- EDSA N/A
- Revenue
- XBIO $2,500,284.00
- EDSA N/A
- Revenue This Year
- XBIO N/A
- EDSA N/A
- Revenue Next Year
- XBIO $27.78
- EDSA N/A
- P/E Ratio
- XBIO N/A
- EDSA N/A
- Revenue Growth
- XBIO N/A
- EDSA N/A
- 52 Week Low
- XBIO $2.26
- EDSA $1.55
- 52 Week High
- XBIO $5.20
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- XBIO 27.60
- EDSA 53.34
- Support Level
- XBIO $3.25
- EDSA $2.31
- Resistance Level
- XBIO $3.43
- EDSA $2.55
- Average True Range (ATR)
- XBIO 0.24
- EDSA 0.12
- MACD
- XBIO -0.08
- EDSA -0.02
- Stochastic Oscillator
- XBIO 25.63
- EDSA 48.28
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.